Microdosing a GLP-1: sold as a product, tested as nothing
Microdosing a GLP-1 means deliberately staying at or under the starting dose instead of climbing to the one the trials used. Zepbound's own label says the 2.5 mg starting dose is not approved as a maintenance dosage. No randomized trial has tested microdosing, and the same trial filter that finds zero for it finds 107 microdosing trials of other things.
What this comes down to
- Wegovy is initiated at 0.25 mg for four weeks and escalated to a maintenance dose of 2.4 mg or 1.7 mg once weekly. The starting dose is a ramp, not a destination.
- Zepbound's label states outright that the 2.5 mg starting dosage is for treatment initiation and is not approved as a maintenance dosage.
- Zero randomized trials of GLP-1 microdosing exist in PubMed. Nine records mention it at all, and not one of them is a trial — six are commentaries or letters, and two are unrelated hits.
- The FDA has received adverse event reports tied to patients measuring and self-administering incorrect doses of compounded semaglutide.
What the approved labels say the doses are
Wegovy starts at 0.25 mg once weekly for four weeks, then climbs on a fixed schedule to a maintenance dose of 2.4 mg, or 1.7 mg for people who cannot tolerate the higher one[1]. The escalation exists to limit gastrointestinal side effects, not to find the lowest dose that works. The trials measured weight change at the maintenance dose.
Zepbound is blunter. Its label sets the starting dosage at 2.5 mg once weekly for four weeks and then says the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage[2]. Maintenance is 5, 10 or 15 mg, and 15 mg is the ceiling.
Microdosing puts you at or below a dose the manufacturer specifically says is not a maintenance dose. That isn't the same as saying it does nothing. It means the evidence you would use to decide either way was never generated.
The trial record
There's none. Filtered to randomized trials in humans, microdosing plus any GLP-1 term returns zero papers in PubMed. The identical filter with the GLP-1 terms removed returns 107 microdosing trials, so the filter works — the subject is what is empty.
PubMed, via the E-utilities API
(microdos*[tiab] OR "micro-dos*"[tiab]) AND (semaglutide[tiab] OR tirzepatide[tiab] OR "GLP-1"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 0. Positive control — microdosing of anything, identical filter — returned 107 through the identical filter in the same session.
Unfiltered, the microdosing and GLP-1 terms return nine records in total. All nine were read: six are commentaries, letters or a published comment on one of those letters, one is an assay development paper, and two are unrelated hits — a microneedle patch and a psilocybin study in mice. Not one is a trial.
What does exist is clinicians writing about it. Two of the nine records are letters in Obesity and Diabetes Care from hospital pharmacy and endocrinology groups, on splitting doses out of multi-dose pens[3][4]. They describe the practice, name the safety and accuracy questions, and don't report an outcome, because nobody has measured one.
The part that has produced actual harm reports
Microdosing usually means drawing a fraction of a dose yourself. The FDA has received multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide — errors from patients measuring and self-administering the wrong amount, and in some cases from clinicians miscalculating[5].
Compounded vials are drawn with an insulin syringe marked in units, while the dose is prescribed in milligrams. The conversion depends on the vial's concentration, which is not standardized between compounders. Getting a new vial from a new pharmacy is when this goes wrong.
What sellers charge for a microdose
Three sellers on our roster price a microdose as its own product. Where the same seller also publishes a full-dose price for the same named drug, the microdose is the cheaper line — which is the practical reason most people are offered one. NiceRx is the clearest example, and the table shows both of its lines side by side.
| Seller | Microdose line | A month | Full-dose line | A month |
|---|---|---|---|---|
| NiceRx | semaglutide microdose | $149 | semaglutide | $199 |
| NiceRx | tirzepatide microdose | $189 | tirzepatide | $299 |
| Lemonaid Health | compounded semaglutide microdoses | $199 | compounded semaglutide | $299 |
| Lemonaid Health | compounded tirzepatide microdoses | $199 | compounded tirzepatide | $299 |
| TelePeptide | microdose GLP-1 | $149 | Not published | — |
Microdose lines, beside the same seller's full-dose line where one exists
One of those lines never names a molecule at all, which means there's no full-dose price to compare it against on that seller's own page. Whether a company publishes what a single month costs, for every drug it sells, is the thing our grade is built on, and it's why a cheaper line isn't automatically a better deal.
Questions people actually ask
What does microdosing a GLP-1 mean?
Taking a dose at or below the approved starting dose as an ongoing regimen, rather than escalating to the maintenance dose the trials used. In practice it usually means drawing a fraction of a vial or pen yourself, week after week.
Is there any research on microdosing semaglutide or tirzepatide?
No randomized trial. PubMed returns zero through a standard trial filter, while the same filter finds 107 microdosing trials of other substances. Nine records mention GLP-1 microdosing at all, and they are commentaries, reviews and unrelated hits rather than trials.
Why do telehealth companies sell a microdose at a lower price?
A microdose uses less drug, so it costs the seller less to fill. Where a seller on our roster publishes both, the microdose line is the cheaper of the two. That's a supply fact, not a clinical finding about which dose is right for you.
Is microdosing dangerous?
The dose itself is lower than the one studied, so the drug-related risk isn't the concern. The measuring is. The FDA has received adverse event reports, some requiring hospitalization, tied to patients and clinicians getting the dose calculation wrong with compounded injectable semaglutide.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- WEGOVY (semaglutide) injection, for subcutaneous use — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2024. Source · Document dated April 2024Initiation at 0.25 mg once weekly for four weeks, a fixed escalation schedule titrating every four weeks, and a maintenance dosage in adults of either 2.4 mg (recommended) or 1.7 mg once weekly.
- ZEPBOUND (tirzepatide) injection, for subcutaneous use — FDA prescribing information. U.S. Food and Drug Administration, Structured Product Labeling, 2026. Source · Document dated August 2026A starting dosage of 2.5 mg once weekly for four weeks, the statement that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage, maintenance dosages of 5, 10 or 15 mg once weekly, and a maximum of 15 mg.
- One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens. Diabetes Care, 2025. PMID 39808463 · doi:10.2337/dc24-2575 · A peer-reviewed letter from a hospital pharmacy and endocrinology group describing the practice of microdosing semaglutide from multidose pens. It reports no outcome data because none exists.
- Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens. Obesity (Silver Spring), 2026. PMID 42244165 · doi:10.1002/oby.70253 · A 2026 commentary in Obesity on the considerations raised by microdosing tirzepatide from multi-dose pens, one of the nine PubMed records on the subject and not a trial.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026. Source · Document dated September 2026Multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide, resulting from patients measuring and self-administering incorrect doses and in some cases from health care professionals miscalculating doses.